Clovis Oncology CLVS today announced that rociletinib, the
company's oral targeted covalent (irreversible) mutant-selective inhibitor
of epidermal growth factor receptor (EGFR) in development for the treatment
of EGFR-mutated, T790M positive non-small cell lung cancer (NSCLC), is the
subject of four mini-oral presentations and two poster sessions at the
16(th) World Conference on Lung Cancer. Hosted by the International
Association for the Study of Lung Cancer (IASLC), the conference will take
place September 6-9, 2015 in Denver.
"We look forward to sharing updated data from the pivotal TIGER-X trial,
analyzing the clinical activity of rociletinib in multiple subsets of
patients with advanced EGFR mutant NSCLC, specifically in those with a
history of CNS metastases, as well as in patients with T790M negative
disease," said Patrick J. Mahaffy, President and CEO of Clovis Oncology.
"The coming months are shaping up to be a very busy and important time for
rociletinib, as we move forward with our pivotal TIGER clinical trial
program and prepare for potential product launches in both the United States
and Europe."
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in